Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Neisseria MeningitidisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

Haemophilus influenzae type b- and meningococcal (vaccine)

Trial Locations (16)

4009

GSK Investigational Site, Almeira

28007

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28047

GSK Investigational Site, Madrid

28905

GSK Investigational Site, Getafe

28922

GSK Investigational Site, Alcorcón

28935

GSK Investigational Site, Móstoles/Madrid

29010

GSK Investigational Site, Málaga

47010

GSK Investigational Site, Valladolid

48013

GSK Investigational Site, Basurto/Bilbao

08025

GSK Investigational Site, Barcelona

08950

GSK Investigational Site, Barcelona

09005

GSK Investigational Site, Burgos

07014

GSK Investigational Site, Palma de Mallorca

Unknown

GSK Investigational Site, Vélez-Málaga

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects | Biotech Hunter | Biotech Hunter